Protein Aggregates



The analysis of the aggregation phenomenon of therapeutic proteins is of crucial importance as more and more pharmaceutical products are proteins or peptides. CovalX introduces a unique tool for the direct characterization of therapeutic protein samples based on High-Mass MALDI mass spectrometry.

Therapeutic Antibody Aggregates

High-Mass MALDI TOF analysis (CovalX HM1) of aggregated sample of the therapeutic protein Hab41 before (black) and after (red) cross-linking. The sample has been submitted to SEC before cross-linking protocol with K200 MALDI MS Stabilization Kit.

The fraction analyzed exhibit a dimer (350 kDa). The high-mass analysis allow to distinguish between covalent and non covalent aggregation.

High Mass MALDI ToF analysis of an aggregated sample of therapeutic protein Hab42 before (black) and after (red) cross-linking. The sample has been submitted to SEC before cross-linking protocol using K200 MALDI MS stabilization kit. The fraction analyzed exhibits a dimer (303 kDa) and hexamer (910 kDa).

 

For more details concerning protein aggregates analysis, feel free to contact our Customer Support Centers or email cro@covalx.com